Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective

被引：0
|
作者：
Sofrygin, O.
Delea, T. E.
Tappenden, P.
Karnon, J.
Browning, D.
Amonkar, M.
Lykopoulos, K.
Cameron, D. A.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[3] Univ Adelaide, Dept Publ Hlth, Adelaide, SA, Australia
[4] GlaxoSmithKline Hlth Outcomes Oncol, London, England
[5] GlaxoSmithKline, Collegeville, PA USA
[6] GlaxoSmithKline Global Hlth Outcomes, London, England
[7] Univ Edinburgh, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FOR WOMEN WITH HER2+METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND
    Farkkila, N.
    Torvinen, S.
    Bergius, S.
    Delea, T.
    Sofrygin, O.
    Walker, M.
    VALUE IN HEALTH, 2008, 11 (06) : A466 - A466
  • [22] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [23] Neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in Asians with HER2+metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
    Dai, M. S.
    Feng, Y. H.
    Chen, S. W.
    Masuda, N.
    Sangai, T.
    Yau, T.
    Kwong, A.
    Ngan, R.
    Yap, Y. S.
    Ang, P. C. S.
    Ow, S.
    Lee, K. S.
    Kim, S. B.
    Chung, H. C.
    Keyvanjah, K.
    Bebchuk, J.
    Chen, M-C. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1259 - S1259
  • [24] Role of tumor infiltrating lymphocytes (TILs) in HER2+metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L plus C) (EMILIA Trial).
    Badve, Sunil S.
    Gokmen-Polar, Yesim
    Hoersch, Silke
    Xu, Jin
    Ruschoff, Josef
    de Haas, Sanne
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)
    McNamara, S.
    Moore, L.
    Ray, J.
    VALUE IN HEALTH, 2010, 13 (07) : A269 - A269
  • [26] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Xu, L
    Song, S
    Zhu, J
    Luo, R
    Li, L
    Jiao, S
    Pan, H
    Tao, M
    Su, Y
    Liu, D
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [27] A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (PTS) with HER2-positive metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Sunchang
    Chen, Li
    Tao, Min
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2006, 17 : 76 - 77
  • [28] Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.
    Ales-Martinez, Jose E.
    Filipovich, Elena
    Garcia Llano, Juan Luis
    Ceballos Viro, Jaime
    Sanchez-Escribano, Ricardo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Cost-effectiveness analysis of pertuzumab plus trastuzumab for advanced HER2-positive breast cancer in Brazil: A public health system perspective
    Carvalho, Adriana C.
    Vasconcelos, Vivian C. A.
    Sasse, Andre D.
    CANCER RESEARCH, 2018, 78 (04)
  • [30] Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
    Dai, Ming Shen
    Feng, Yin Hsun
    Chen, Shang Wen
    Masuda, Norikazu
    Yau, Thomas
    Chen, Shou Tung
    Lu, Yen Shen
    Yap, Yoon Sim
    Ang, Peter C. S.
    Chu, Sung Chao
    Kwong, Ava
    Lee, Keun Seok
    Ow, Samuel
    Kim, Sung Bae
    Lin, Johnson
    Chung, Hyun Cheol
    Ngan, Roger
    Kok, Victor C.
    Rau, Kun Ming
    Sangai, Takafumi
    Ng, Ting Ying
    Tseng, Ling Ming
    Bryce, Richard
    Bebchuk, Judith
    Chen, Mei Chieh
    Hou, Ming Feng
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 665 - 676
12345